PE20081256A1 - Triazalopiridacina como modulador de la actividad proteina cinasa - Google Patents

Triazalopiridacina como modulador de la actividad proteina cinasa

Info

Publication number
PE20081256A1
PE20081256A1 PE2007001436A PE2007001436A PE20081256A1 PE 20081256 A1 PE20081256 A1 PE 20081256A1 PE 2007001436 A PE2007001436 A PE 2007001436A PE 2007001436 A PE2007001436 A PE 2007001436A PE 20081256 A1 PE20081256 A1 PE 20081256A1
Authority
PE
Peru
Prior art keywords
halogen
triazalopyridacine
modulator
protein kinase
kinase activity
Prior art date
Application number
PE2007001436A
Other languages
English (en)
Inventor
Christopher Ronald Smith
Pierre-Yves Bounaud
Elizabeth Anne Jefferson
Patrick S Lee
Eduardo Torres
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of PE20081256A1 publication Critical patent/PE20081256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN DERIVADO DE TRIAZALOPIRIDACINA DE FORMULA (I), DONDE A ES UN GRUPO ARILO O HETEROARILO; Q ES H, HALOGENO, AMINO, PERFLUOROALQUILO, ENTRE OTROS; T ES CH2, CH(HALOGENO), C(HALOGENO), ENTRE OTROS; X ES N O CR2; R1 Y R2 SON H, HALOGENO, NITRO, CIANO, OH, ENTRE OTROS; R28' Y R28'' SON H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R35 ES UN ENLACE, H, HALOGENO, NITRO, OH, ENTRE OTROS; z ES UN ENTERO DE 0 A 3. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE LA TIROSINA CINASAS, PARTICULARMENTE, MET Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2007001436A 2006-10-23 2007-10-23 Triazalopiridacina como modulador de la actividad proteina cinasa PE20081256A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
PE20081256A1 true PE20081256A1 (es) 2008-10-13

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001436A PE20081256A1 (es) 2006-10-23 2007-10-23 Triazalopiridacina como modulador de la actividad proteina cinasa

Country Status (16)

Country Link
US (1) US8071581B2 (es)
EP (1) EP2081937B1 (es)
JP (1) JP2010507577A (es)
KR (1) KR101083177B1 (es)
AU (1) AU2007309237B2 (es)
BR (1) BRPI0717317A2 (es)
CA (1) CA2667453A1 (es)
DK (1) DK2081937T3 (es)
EA (1) EA016527B1 (es)
ES (1) ES2393132T3 (es)
MX (1) MX2009004060A (es)
PE (1) PE20081256A1 (es)
PL (1) PL2081937T3 (es)
PT (1) PT2081937E (es)
TW (1) TW200833692A (es)
WO (1) WO2008051805A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3327016T3 (pl) 2006-04-07 2021-10-04 Vertex Pharmaceuticals Incorporated Wytwarzanie modulatorów transporterów posiadających kasetę wiążącą ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
TW200817410A (en) 2006-08-07 2008-04-16 Incyte Corp Triazolotriazines as kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
TWI472529B (zh) * 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
WO2010068292A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
EP2406264A4 (en) * 2009-03-09 2012-08-08 Univ California SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINE AND GABAA RECEPTORS
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
IN2012DN01453A (es) 2009-08-20 2015-06-05 Novartis Ag
HRP20221090T1 (hr) * 2009-12-31 2022-11-25 Hutchison Medipharma Limited Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe
EP2531509B1 (en) 2010-02-03 2016-10-05 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR101984225B1 (ko) * 2010-04-22 2019-05-30 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
WO2011153192A2 (en) * 2010-06-01 2011-12-08 Angion Biomedica Corp. Cytochrome p450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CA2848518C (en) 2011-09-27 2019-06-18 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
SG11201406185WA (en) 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
MX358508B (es) 2012-10-16 2018-08-22 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
US9846345B2 (en) 2013-02-28 2017-12-19 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
AU2014230812B2 (en) * 2013-03-13 2016-04-07 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
US20140303121A1 (en) * 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
PL2970265T3 (pl) * 2013-03-15 2018-11-30 Plexxikon Inc. Heterocykliczne związki i ich zastosowania
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
PT3925607T (pt) 2014-04-15 2023-09-26 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
US9988374B2 (en) 2014-08-11 2018-06-05 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
CN114681608A (zh) 2015-04-13 2022-07-01 戊瑞治疗有限公司 癌症组合疗法
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
CN113861198A (zh) * 2020-06-30 2021-12-31 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
KR100932677B1 (ko) * 2001-08-10 2009-12-22 요코하마 티엘오 가부시키가이샤 열전달 장치
KR101412675B1 (ko) * 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. 티로신 키나제 모듈레이터로서의 트리아졸로피리다진
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Also Published As

Publication number Publication date
PL2081937T3 (pl) 2013-01-31
BRPI0717317A2 (pt) 2013-10-22
EP2081937B1 (en) 2012-09-12
PT2081937E (pt) 2012-10-15
US20100120739A1 (en) 2010-05-13
AU2007309237B2 (en) 2012-03-22
JP2010507577A (ja) 2010-03-11
DK2081937T3 (da) 2012-10-01
US8071581B2 (en) 2011-12-06
KR101083177B1 (ko) 2011-11-11
EP2081937A2 (en) 2009-07-29
EA016527B1 (ru) 2012-05-30
ES2393132T3 (es) 2012-12-18
KR20090069303A (ko) 2009-06-30
EA200970402A1 (ru) 2009-10-30
TW200833692A (en) 2008-08-16
CA2667453A1 (en) 2008-05-02
MX2009004060A (es) 2009-06-19
AU2007309237A1 (en) 2008-05-02
WO2008051805A2 (en) 2008-05-02
WO2008051805A3 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
EA200700119A1 (ru) Соединения и способы лечения дислипидемии
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
EA200601785A1 (ru) Соединения и способы лечения дислипидемии
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
PE20060501A1 (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
PE20070602A1 (es) Compuestos de carboxiamina como moduladores de histona desacetilasa
BRPI0513310A (pt) análogos de tetrapeptìdeo
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
ATE461188T1 (de) Verstärker von glutamat-rezeptoren
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200800015A1 (ru) Аминопиримидины в качестве модуляторов киназы
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
AR054252A1 (es) Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina

Legal Events

Date Code Title Description
FD Application declared void or lapsed